TIGAR and non-small cell lung carcinoma: In order to understand the role of TIGAR and its potential use as a biomarker in NSCLC, an immunohistochemical analysis of 72 NSCLC patients was conducted, and it showed that both TIGAR and Met expression correlated positively with late stages of lung cancer.